MedTrace Logo

The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time

NCT07661030 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2026-06-22

No results posted yet for this study

Summary

To confirm that initiating Dotinurad for uric acid uric acid lowering during the acute phase of gout is non-inferior to initiating it after the acute phase of gout has subsided, and to analyze whether initiating Dotinurad treatment during the acute phase will increase the pain level, the recurrence rate of gout, and the inflammatory level of patients.

Conditions

Interventions

DRUG

Dotinurad

The drug used in the treatment group (from week 1 to 4)and the control group (from week 3 to 4). This is the main intervention factor of the study.

DRUG

colchicine

The drugs used throughout the treatment and control groups. In this design, it is part of the background treatment or the standard treatment.

DRUG

etoricoxib

The drugs used by the treatment group and the control group in the first week. It is also part of the background treatment.

Sponsors & Collaborators

  • The Affiliated People's Hospital of Ningbo University

    collaborator OTHER_GOV

  • Wenzhou Central Hospital

    collaborator OTHER

  • Yuyao People's Hospital

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-30
Primary Completion
2027-07-30
Completion
2027-07-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07661030 on ClinicalTrials.gov